Business Context and Reporting Period
This Form 10-Q covers the quarterly and six-month periods ended June 30, 1997, for Schering-Plough Corporation. The company operates primarily in pharmaceutical and health care products. Notable corporate actions during this period include a 2-for-1 stock split effective June 3, 1997, and the acquisition of the worldwide animal health business of Mallinckrodt Inc. on June 30, 1997, for approximately $490 million.
Key Financial Metrics
| Metric | Three Months Ended June 30, 1997 | Six Months Ended June 30, 1997 |
|---|---|---|
| Sales | $1,719.8 million | $3,287.9 million |
| Net Income | $373.1 million | $748.4 million |
| Earnings Per Share (EPS) | $0.51 | $1.02 |
| Income Before Taxes Margin | 28.7% | 30.1% |
| Cost of Sales Margin | 19.2% | 18.8% |
| Operating Cash Flow (6 months) | $719.6 million | |
| Cash and Equivalents (End of Period) | $699.2 million | |
| Total Debt (Short-term + Long-term) | $1,116.2 million |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated sales increased 16% in the quarter and 15% for the six-month period compared to 1996. Excluding foreign currency fluctuations, growth was 19% and 18%, respectively.
- Profitability: Net income rose 18% in the quarter and 16% for the six months. EPS increased 19% to $0.51 for the quarter and 16% to $1.02 for the six months.
- Product Performance:
- CLARITIN: Sales reached $536 million (quarter) and $889 million (six months), driving significant growth in allergy/respiratory products.
- PROVENTIL: Sales declined 25% in the quarter and 36% for the six months due to generic competition.
- INTRON A: Increased utilization drove growth in anti-infective and anticancer products.
- Acquisition Impact: The Mallinckrodt animal health business acquisition ($490 million) is reflected in the balance sheet but results of operations will begin in the third quarter of 1997.
Guidance, Outlook, and Risks
- Outlook: Management expects continued strong performance from CLARITIN and INTRON A. However, generic competition for PROVENTIL is expected to continue negatively affecting sales and profitability.
- Legal Contingencies: The company is a defendant in over 160 antitrust actions. A federal class action settlement of $22.1 million (payable over three years) was approved, though new litigation regarding the implementation of settlement commitments has commenced.
- Regulatory and Market Risks: Operations face risks from government-mandated cost containment, price cuts, and restrictions on physician prescriptions globally. Patent disputes and delays in regulatory approvals for new products remain significant uncertainties.
- Capital Allocation: The company has a $500 million share repurchase program, which was approximately 74% complete as of June 30, 1997. Dividends per share were increased to $0.19 for the quarter.
Investor Verification Checklist
- Verify the impact of the 2-for-1 stock split on historical per-share data comparisons.
- Monitor the integration and financial contribution of the Mallinckrodt animal health business starting in Q3 1997.
- Track the status of the $22.1 million antitrust settlement and the outcome of the new class action filed in April 1997.
- Assess the trajectory of PROVENTIL sales decline against the growth of CLARITIN and INTRON A.
- Review the progress of the $500 million share repurchase program and future dividend declarations.